Core Viewpoint - The completion of the H-share full circulation marks a significant step for the company in terms of equity structure and capital operations, enhancing liquidity and governance while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - The company announced the conversion of 182,645,856 non-listed shares into H-shares, which will start trading on February 5, 2026, increasing the total number of H-shares to 346,074,397 [1] - This move is expected to expand the liquidity of the company's shares listed in Hong Kong and improve market pricing effectiveness and fairness [1] Group 2: Financial Performance and Strategic Development - The company became the first Hong Kong-listed innovative pharmaceutical company to achieve full-year profitability in 2023, driven by product sales [1] - The stable cash flow generated from biosimilars will support ongoing innovation and research and development, as the company transitions into a "Globalization 2.0" development phase characterized by capability building and innovation [1]
复宏汉霖完成H股全流通 扩大流通规模助力全球化战略 释放长期投资价值